Mounjaro Tirzepatide 5MG

Description

Tirzepatide 5mg: Dual GLP-1 & GIP Receptor Agonist for Metabolic Research

Lyophilised — MUST BE RECONSTITUTED

Tirzepatide is a synthetic peptide and dual incretin mimetic that simultaneously activates both glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) receptors. Originally developed in the context of type 2 diabetes research, Tirzepatide is now studied extensively for its effects on metabolic regulation, glucose homeostasis, and adipose tissue dynamics.

Its dual-receptor mechanism distinguishes it from single-agonist GLP-1 compounds such as Semaglutide. By engaging both incretin pathways concurrently, Tirzepatide produces a broader metabolic response across pancreatic, hypothalamic, and peripheral tissue targets — making it a subject of significant interest in cardiometabolic and obesity research.

Tirzepatide is supplied here in lyophilised research vial format for laboratory investigation purposes only.

Product Summary

Mechanism of Action

Tirzepatide functions as a dual GLP-1 and GIP receptor agonist. These two receptors are central components of the incretin system — a set of hormonal pathways triggered by nutrient ingestion that regulate postprandial insulin secretion and glucose disposal.

GLP-1 receptor activation promotes glucose-dependent insulin release from pancreatic beta cells, suppresses glucagon secretion from alpha cells, and engages hypothalamic pathways involved in energy intake regulation. GIP receptor activation further potentiates insulin secretion and has been shown in preclinical models to influence adipogenesis and lipid metabolism at the tissue level.

The concurrent activation of both pathways by Tirzepatide produces a synergistic incretin response, which has been the subject of investigation in the context of obesity, insulin resistance, and cardiometabolic disease across multiple large-scale clinical trial programmes.

In Vivo Research Findings

• Significant body weight reduction observed across SURMOUNT-1 and SURMOUNT-4 trial programmes in obese and overweight subject populations
• Improved glycaemic control including reductions in HbA1c and fasting plasma glucose in type 2 diabetes models
• Enhanced insulin sensitivity via improved peripheral glucose uptake and reduced glucagon secretion
• Reduced visceral adiposity in metabolic and obesity research models
• Favourable lipid profile modulation including reductions in LDL cholesterol and triglycerides observed in cardiometabolic studies
• Gastric motility reduction contributing to altered nutrient absorption kinetics in gastrointestinal research
• Anti-inflammatory signalling investigated in the context of cardiovascular and longevity-related research pathways

Research Applications

• Obesity and adipose tissue biology research
• Type 2 diabetes and insulin resistance models
• Cardiometabolic disease investigation
• Incretin system and pancreatic function studies
• Energy homeostasis and hypothalamic signalling research
• Comparative incretin pharmacology (GLP-1 vs dual agonism)

Studies & Additional Information

Tirzepatide has been investigated in the SURPASS clinical trial series (SURPASS-1 through SURPASS-5) for glycaemic outcomes in type 2 diabetes, and in the SURMOUNT series (SURMOUNT-1, SURMOUNT-2, SURMOUNT-4) for weight management in obese and overweight populations. Findings from these programmes have been published in peer-reviewed journals including The New England Journal of Medicine and Nature Medicine.

Preclinical research has further explored Tirzepatide’s role in non-alcoholic fatty liver disease (NAFLD), mitochondrial function, and inflammatory pathway modulation, establishing a broad research base beyond its primary metabolic applications.

Disclaimer: Tirzepatide is supplied strictly for laboratory research purposes. It is not intended for human consumption, therapeutic use, or self-administration. All research involving this compound should be conducted by qualified personnel in an appropriate laboratory setting and in accordance with applicable regulations.

Frequently Asked Questions

What makes Tirzepatide different from GLP-1 receptor agonists like Semaglutide?

Tirzepatide activates both GLP-1 and GIP receptors simultaneously, whereas Semaglutide targets the GLP-1 receptor alone. This dual agonism produces a broader incretin response, which has shown greater metabolic effects in comparative clinical research.

What biological pathways does Tirzepatide engage?

Tirzepatide engages the GLP-1 and GIP incretin pathways, which regulate pancreatic insulin and glucagon secretion, hypothalamic energy intake signalling, and peripheral glucose disposal. Its GIP component also influences adipose tissue biology in preclinical models.

What research areas is Tirzepatide most studied in?

The primary research focus includes obesity, type 2 diabetes, insulin resistance, and cardiometabolic disease. Secondary areas of investigation include NAFLD, cardiovascular outcomes, and longevity-related metabolic pathways.

What is the incretin system and how does Tirzepatide relate to it?

The incretin system comprises gut-derived hormones, primarily GLP-1 and GIP, that are released in response to nutrient ingestion and regulate insulin secretion and glucose metabolism. Tirzepatide is a synthetic dual incretin mimetic designed to activate both of these receptor pathways simultaneously.

Does Tirzepatide require reconstitution before use in research?

Yes. This product is supplied in lyophilised (freeze-dried) form and must be reconstituted with an appropriate sterile diluent, such as Bacteriostatic Water, prior to use in a laboratory setting.